DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, In | ko |
dc.contributor.author | Kim, Yumin | ko |
dc.contributor.author | Lee, Heung Kyu | ko |
dc.date.accessioned | 2023-12-04T07:01:37Z | - |
dc.date.available | 2023-12-04T07:01:37Z | - |
dc.date.created | 2023-12-04 | - |
dc.date.created | 2023-12-04 | - |
dc.date.issued | 2023-10 | - |
dc.identifier.citation | FRONTIERS IN IMMUNOLOGY, v.14 | - |
dc.identifier.issn | 1664-3224 | - |
dc.identifier.uri | http://hdl.handle.net/10203/315684 | - |
dc.description.abstract | Although gamma delta T cells comprise a small population of T cells, they perform important roles in protecting against infection and suppressing tumors. With their distinct tissue-localizing properties, combined with their various target recognition mechanisms, gamma delta T cells have the potential to become an effective solution for tumors that do not respond to current therapeutic procedures. One such tumor, glioblastoma (GBM), is a malignant brain tumor with the highest World Health Organization grade and therefore the worst prognosis. The immune-suppressive tumor microenvironment (TME) and immune-evasive glioma stem cells are major factors in GBM immunotherapy failure. Currently, encouraged by the strong anti-tumoral function of gamma delta T cells revealed at the preclinical and clinical levels, several research groups have shown progression of gamma delta T cell-based GBM treatment. However, several limitations still exist that block effective GBM treatment using gamma delta T cells. Therefore, understanding the distinct roles of gamma delta T cells in anti-tumor immune responses and the suppression mechanism of the GBM TME are critical for successful gamma delta T cell-mediated GBM therapy. In this review, we summarize the effector functions of gamma delta T cells in tumor immunity and discuss current advances and limitations of gamma delta T cell-based GBM immunotherapy. Additionally, we suggest future directions to overcome the limitations of gamma delta T cell-based GBM immunotherapy to achieve successful treatment of GBM. | - |
dc.language | English | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.title | γδ T cells as a potential therapeutic agent for glioblastoma | - |
dc.type | Article | - |
dc.identifier.wosid | 001096291600001 | - |
dc.identifier.scopusid | 2-s2.0-85175820561 | - |
dc.type.rims | ART | - |
dc.citation.volume | 14 | - |
dc.citation.publicationname | FRONTIERS IN IMMUNOLOGY | - |
dc.identifier.doi | 10.3389/fimmu.2023.1273986 | - |
dc.contributor.localauthor | Lee, Heung Kyu | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Review | - |
dc.subject.keywordAuthor | glioblastoma | - |
dc.subject.keywordAuthor | tumor microenvironment | - |
dc.subject.keywordAuthor | gamma delta T cells | - |
dc.subject.keywordAuthor | immunotherapy | - |
dc.subject.keywordAuthor | engineering | - |
dc.subject.keywordPlus | CENTRAL-NERVOUS-SYSTEM | - |
dc.subject.keywordPlus | TUMOR-TREATING FIELDS | - |
dc.subject.keywordPlus | ADJUVANT TEMOZOLOMIDE | - |
dc.subject.keywordPlus | IMMUNE CELLS | - |
dc.subject.keywordPlus | BRAIN | - |
dc.subject.keywordPlus | RADIATION | - |
dc.subject.keywordPlus | RESPONSES | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | EXPRESSION | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.